Breaking News
Close
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

GSK plc (GLAXF)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
21.9900 +0.8900    +4.22%
27/06 - Closed. Currency in USD ( Disclaimer )
  • Volume: 592
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 21.2000 - 21.9900
Type:  Equity
Market:  United States
ISIN:  GB0009252882 
S/N:  000925288
GSK plc 21.9900 +0.8900 +4.22%
IndustryPharmaceuticals
SectorHealthcare
Employees

90096

Equity Type

ORD

GSK plc, formerly GlaxoSmithKline PLC is a global healthcare company. The Company is focused to improve the quality of human life by helping people. The Company operates through three core businesses: Pharmaceuticals, Vaccines and Consumer Healthcare. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency viruses (HIV), immuno-inflammation and oncology. It also focuses on immunology, human genetics, and advanced technologies to deliver transformational new medicines for patients. The Company's research and development focuses on developing vaccines against infectious diseases that combine high medical needs and market potential. The Company's Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, minerals and supplements. It provides prescription medicines, vaccines, and consumer healthcare products.

Contact Information

Phone 44 20 8047 5000
Fax -

Top Executives

Name Age Since Title
Iain James Mackay 59 2019 CFO & Executive Director
Emma N. Walmsley 51 2011 CEO & Director
Hal V. Barron 58 2018 Chief Scientific Officer, President of R&D and Director
Manvinder Singh Banga 67 2015 Senior Independent Non-Executive Director
Jonathan Richard Symonds 62 2019 Non-Executive Chairman
Lynn Laverty Elsenhans 64 2012 Independent Non-Executive Director
Anne C. Beal - 2021 Independent Non-Executive Director
Charles A. Bancroft 61 2020 Independent Non-Executive Director
Urs Rohner 62 2015 Independent Non-Executive Director
Harry C. Dietz - 2022 Independent Non-Executive Director
Jesse L. Goodman 70 2016 Independent Non-Executive Director
Laurie H. Glimcher 70 2017 Independent Non-Executive Director
Vivienne Cox 63 2016 Independent Non-Executive Director & Workforce Engagement Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GSK Comments

Write your thoughts about GlaxoSmithKline PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lisa Chapman
Lisa Chapman 3 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Consistency is the key, I've been investing with @Natalie Jason for months now and I've made a lot of profit from her. Most of those traders who offer to give you 300% of what ever you invest might scam you of your hard earn money. Crypto ain't that easy you know, I recommend Mrs Natalie Jason to every investors out there, Dm Natalie Jason👉 on face🚹book or Natalie Jasonfx_trade on👉 tele🚹gram
kennedy Miley
kennedy Miley 6 hours ago
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you're seeing this and have been searching for a reliable broker not traceable to scam and no payment delays; you've got your self covered investing and being guided by MR LENNART either as a professional or novice. if you've being badly affected by your past, Mr Lennart Antero is here to help you recover and be rest assured that there's no loosing. I'm benefiting greatly on a daily basis and would like others to join in the queue. Face💢book ⏩ Lennart Antero
Anon Anon
Anon Anon Jan 17, 2022 11:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move
Anon Anon
Anon Anon Dec 09, 2021 8:46
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Moving closer to my 1800 tgt (posted on March 30). This stock pays very generous dividend I have to say
Will Strath
Will Strath Nov 05, 2021 12:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ex-div in 13 days time. why risk selling now when you might not get back on the boat? pretty sure the company split will reach equivalent of 2000+ for the two new companies.
Craig Nelson
Craig Nelson Nov 05, 2021 9:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1587.80 looking at my previous comment "what do i know" near yearly HIGHS
Anon Anon
Anon Anon Nov 01, 2021 8:16
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Breakout. Strong buy
Craig Nelson
Craig Nelson Oct 16, 2021 18:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1399.60p described as a good Divi stock but where's the potential capital growth... will wait for sub 1200.00p
Robin Mitha
Robin Mitha Jun 23, 2021 12:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The current CEO seems to have lost confidence, time for a change to inject new life into the company
simon stirling
simon stirling Jun 23, 2021 12:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the news from today remarked that investors present applauded during the event.
Robin Mitha
Robin Mitha Jun 23, 2021 12:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the question is what percentage of GSK shareholders attended, most big investors gont go to such events
simon stirling
simon stirling Jun 23, 2021 12:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
while true, until we know who attended it's hard to gauge lost confidence. at the start of the day pre share holder day, the share price was 20p down, that swung to 40p up at one point, hardly signals negativity
STEPHEN CLARKE
Engweliri Jun 11, 2021 13:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Seems to me that a stake is being built, especially from the area of £13.25 upwards. We already have the "activist" investment fund but another buyer is around. Seems similar to whats been happening in BT shares over the last few weeks. Stay long and collect dividends on the way. Hopefully
Mo Ahmadi
Mo Ahmadi Jun 11, 2021 13:10
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what will happen when the split happens in 2022?!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Our Apps
DOWNLOAD APPApp store
Investing.com
© 2007-2022 Fusion Media Limited. All Rights Reserved.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
  • Sign up for FREE and get:
  • Real-Time Alerts
  • Advanced Portfolio Features
  • Personalized Charts
  • Fully-Synced App
Continue with Google
or
Sign up with Email